Assessing Cogent Biosciences (COGT) Valuation After PEAK Phase 3 Success And FDA Priority Review
Cogent Biosciences (COGT) released detailed PEAK Phase 3 data for its bezuclastinib and sunitinib combination in imatinib-treated GIST, alongside FDA […]







